Nothing Special   »   [go: up one dir, main page]

PL2928884T3 - Nowe pochodne benzoimidazoli jako antagoniści EP4 - Google Patents

Nowe pochodne benzoimidazoli jako antagoniści EP4

Info

Publication number
PL2928884T3
PL2928884T3 PL13798684T PL13798684T PL2928884T3 PL 2928884 T3 PL2928884 T3 PL 2928884T3 PL 13798684 T PL13798684 T PL 13798684T PL 13798684 T PL13798684 T PL 13798684T PL 2928884 T3 PL2928884 T3 PL 2928884T3
Authority
PL
Poland
Prior art keywords
antagonists
benzimidazole derivatives
novel benzimidazole
novel
derivatives
Prior art date
Application number
PL13798684T
Other languages
English (en)
Inventor
Olaf Peters
Nico Bräuer
Thorsten Blume
Laak Antonius Ter
Ludwig Zorn
Jens Nagel
Stefan Kaulfuss
Gernot Langer
Joachim Kuhnke
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47325927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2928884(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of PL2928884T3 publication Critical patent/PL2928884T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
PL13798684T 2012-12-06 2013-12-03 Nowe pochodne benzoimidazoli jako antagoniści EP4 PL2928884T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195849 2012-12-06
EP13798684.0A EP2928884B1 (de) 2012-12-06 2013-12-03 Neuartige benzimidazolderivate als ep4-antagonisten

Publications (1)

Publication Number Publication Date
PL2928884T3 true PL2928884T3 (pl) 2017-11-30

Family

ID=47325927

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13798684T PL2928884T3 (pl) 2012-12-06 2013-12-03 Nowe pochodne benzoimidazoli jako antagoniści EP4

Country Status (41)

Country Link
US (1) US9708311B2 (pl)
EP (1) EP2928884B1 (pl)
JP (1) JP6367822B2 (pl)
KR (1) KR20150092248A (pl)
CN (1) CN104854098B (pl)
AP (1) AP3862A (pl)
AR (1) AR093840A1 (pl)
AU (1) AU2013354226B2 (pl)
BR (1) BR112015012555B1 (pl)
CA (1) CA2893630C (pl)
CL (1) CL2015001508A1 (pl)
CR (1) CR20150296A (pl)
CU (1) CU20150056A7 (pl)
CY (1) CY1119200T1 (pl)
DK (1) DK2928884T3 (pl)
EA (1) EA028830B1 (pl)
EC (1) ECSP15022555A (pl)
ES (1) ES2637738T3 (pl)
GT (1) GT201500138A (pl)
HK (1) HK1210139A1 (pl)
HR (1) HRP20171200T1 (pl)
IL (1) IL239026A0 (pl)
JO (1) JO3431B1 (pl)
LT (1) LT2928884T (pl)
MA (1) MA38146B1 (pl)
ME (1) ME02950B (pl)
MX (1) MX2015007135A (pl)
MY (1) MY175272A (pl)
NI (1) NI201500077A (pl)
NZ (1) NZ707825A (pl)
PE (1) PE20151065A1 (pl)
PH (1) PH12015501289A1 (pl)
PL (1) PL2928884T3 (pl)
PT (1) PT2928884T (pl)
RS (1) RS56121B1 (pl)
SI (1) SI2928884T1 (pl)
TN (1) TN2015000250A1 (pl)
TW (1) TWI613198B (pl)
UA (1) UA115576C2 (pl)
UY (1) UY35177A (pl)
WO (1) WO2014086739A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6285866B2 (ja) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. 天然複合ホルモン補充製剤および療法
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2961747B1 (en) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
SG11201601870VA (en) 2013-10-01 2016-04-28 Glaxosmithkline Ip Dev Ltd Compounds for affinity chromatography and for extending the half-life of a therapeutic agent
TW201607943A (zh) * 2013-12-19 2016-03-01 拜耳製藥公司 作為ep4配體之新穎苯并咪唑衍生物
PL3087071T3 (pl) * 2013-12-24 2019-03-29 Bristol-Myers Squibb Company Związki tricykliczne jako środki przeciwrakowe
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN104326937B (zh) * 2014-09-03 2016-08-24 天津市肿瘤研究所 抗肿瘤化合物及其医药用途
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CA3019380A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. ステロイドホルモン薬学的組成物
HUE056716T2 (hu) 2016-09-30 2022-03-28 Vertex Pharma Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására
DK3551622T3 (da) 2016-12-09 2020-11-23 Vertex Pharma Modulator af transmembrankonduktansregulator af cystisk fibrose, farmaceutiske sammensætninger, behandlingsfremgangsmåder og fremgangsmåde til fremstilling af modulatoren
WO2018162562A1 (en) 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
CR20190559A (es) 2017-05-18 2020-02-10 Idorsia Pharmaceuticals Ltd Derivados de fenilo como moduladores del receptor de pge2
CN110621666A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 N-取代吲哚衍生物
US11446298B2 (en) 2017-05-18 2022-09-20 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
TW201900179A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
WO2018210988A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as pge2 receptor modulators
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018309043B2 (en) 2017-08-02 2022-03-31 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS
TWI719349B (zh) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Cftr調節劑之結晶形式及組合物
AU2018380426B2 (en) 2017-12-08 2023-05-18 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3820469A4 (en) * 2018-07-11 2022-04-13 Arrys Therapeutics, Inc. EP4 INHIBITORS AND USE THEREOF
CN113527206B (zh) * 2020-04-17 2022-12-30 上海中泽医药科技有限公司 一种苯并氮杂环类化合物、其制备方法及用途
EP4245301A4 (en) 2020-11-13 2024-08-21 Ono Pharmaceutical Co CANCER TREATMENT BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR
US12016847B2 (en) 2021-03-12 2024-06-25 Bristol-Myers Squibb Company Methods of treating prostate cancer
KR102708701B1 (ko) * 2021-12-27 2024-09-24 에이치케이이노엔 주식회사 벤즈이미다졸 유도체의 제조방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1167680C (zh) 1999-12-27 2004-09-22 日本烟草产业株式会社 稠环化合物及其药物用途
AU2541301A (en) 2000-01-18 2001-07-31 Schering Ag Drospirenone for hormone replacement therapy
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
AU2003214525B2 (en) 2002-04-12 2008-09-25 Pfizer Inc. Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
CA2492305A1 (en) * 2002-07-31 2004-02-05 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
PL376683A1 (pl) 2002-11-15 2006-01-09 Tibotec Pharmaceuticals Ltd. Podstawione indolopirydyny jako związki przeciwinfekcyjne
US6949564B2 (en) 2002-12-18 2005-09-27 Pfizer Inc. NPY-5 antagonists
CA2514220C (en) 2003-01-29 2012-02-28 Pharmagene Laboratories Limited Ep4 receptor antagonists
CA2520281A1 (en) 2003-04-03 2004-10-14 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa recept or complex
TW200512147A (en) 2003-07-25 2005-04-01 Black Clawson Converting Machinery Inc Method and apparatus for splicing webs
EP1663979B1 (en) 2003-09-03 2013-10-09 RaQualia Pharma Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
RU2006137076A (ru) 2004-04-20 2008-04-27 Пфайзер Продактс Инк. (Us) Комбинации, содержащие лиганды рецептора альфа-2-дельта
JP2008504233A (ja) 2004-04-23 2008-02-14 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
CA2565660C (en) 2004-05-04 2009-11-03 Pfizer Inc. Ortho substituted aryl or heteroaryl amide compounds
DE602005026867D1 (de) * 2005-01-19 2011-04-21 Biolipox Ab Entzündungshemmende indol-derivate
ES2392192T3 (es) 2006-04-24 2012-12-05 Merck Canada Inc. Derivados de indol amida como antagonistas del receptor EP4
US7732447B2 (en) * 2006-06-22 2010-06-08 Cephalon, Inc. Fused [d]pyridazin-7-ones
GB0614066D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
FR2904318B1 (fr) * 2006-07-27 2011-02-25 Scras Derives de pyrimidinone et leur utilisation comme medicament
WO2008017164A1 (en) 2006-08-11 2008-02-14 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
EP2114877B1 (en) 2007-02-26 2012-12-26 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
WO2009005076A1 (ja) 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
US20100204487A1 (en) 2007-08-09 2010-08-12 Ian Davies Process for making thiophene carboxamide derivatives
JP5536773B2 (ja) 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ep4受容体アンタゴニストとしてのヘテロ環式アミド誘導体
WO2010117639A2 (en) 2009-03-31 2010-10-14 The Texas A&M University System Inhibition of prostglandin e2 receptors for the treatment of endometriosis
US20110059962A1 (en) 2009-04-22 2011-03-10 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
BR112012020236A2 (pt) * 2010-02-22 2016-05-17 Raqualia Pharma Inc uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero
TW201607943A (zh) * 2013-12-19 2016-03-01 拜耳製藥公司 作為ep4配體之新穎苯并咪唑衍生物

Also Published As

Publication number Publication date
RS56121B1 (sr) 2017-10-31
UY35177A (es) 2014-06-30
JP6367822B2 (ja) 2018-08-01
SI2928884T1 (sl) 2017-09-29
TN2015000250A1 (en) 2016-10-03
US9708311B2 (en) 2017-07-18
CY1119200T1 (el) 2018-02-14
US20160214977A1 (en) 2016-07-28
DK2928884T3 (en) 2017-09-11
CN104854098B (zh) 2018-01-09
KR20150092248A (ko) 2015-08-12
MA38146B1 (fr) 2018-08-31
GT201500138A (es) 2017-10-05
AU2013354226B2 (en) 2017-09-14
PT2928884T (pt) 2017-08-25
CU20150056A7 (es) 2015-10-27
ES2637738T3 (es) 2017-10-16
CA2893630C (en) 2021-02-23
EA201591087A1 (ru) 2015-12-30
LT2928884T (lt) 2017-08-25
HK1210139A1 (en) 2016-04-15
ECSP15022555A (es) 2016-01-29
AP3862A (en) 2016-10-31
BR112015012555A2 (pt) 2017-07-11
EP2928884A1 (de) 2015-10-14
EA028830B1 (ru) 2018-01-31
AP2015008463A0 (en) 2015-05-31
CR20150296A (es) 2015-08-10
TW201422608A (zh) 2014-06-16
CL2015001508A1 (es) 2015-07-24
MA38146A1 (fr) 2018-01-31
BR112015012555B1 (pt) 2022-02-15
AR093840A1 (es) 2015-06-24
NI201500077A (es) 2016-02-15
MY175272A (en) 2020-06-17
NZ707825A (en) 2019-06-28
AU2013354226A1 (en) 2015-06-18
PH12015501289B1 (en) 2015-08-24
TWI613198B (zh) 2018-02-01
PH12015501289A1 (en) 2015-08-24
WO2014086739A1 (de) 2014-06-12
JO3431B1 (ar) 2019-10-20
HRP20171200T1 (hr) 2017-12-15
IL239026A0 (en) 2015-07-30
JP2016501241A (ja) 2016-01-18
ME02950B (me) 2018-07-20
MX2015007135A (es) 2016-02-05
EP2928884B1 (de) 2017-05-24
UA115576C2 (uk) 2017-11-27
PE20151065A1 (es) 2015-08-19
CA2893630A1 (en) 2014-06-12
CN104854098A (zh) 2015-08-19

Similar Documents

Publication Publication Date Title
AP3862A (en) Novel benzimidazole derivatives as ep4 antagonists
HRP20181429T8 (hr) Novi derivati benzimidazola kao inhibitori kinaze
EP2890691A4 (en) BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS
SI2877467T1 (sl) 2-(azaindol-2-il)benzimidazoli kot PAD4 inhibitorji
IL238693A0 (en) Tricyclic benzamidazoles are converted as kinase inhibitors
EP2906040A4 (en) NEW BENZIMIDAZOLE DERRAHYDROPYRANE DERIVATIVES
EP2888007A4 (en) NOVEL BENZIMIDAZOLTETRAHYDROFURANDERIVATE
HK1223355A1 (zh) 作為 配體的苯並咪唑衍生物
EP2818473A4 (en) HETEROCYCLIC COMPOUND
ME02576B (me) Derivati tetrahidropirolotiazina kao inhibitori bace
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
IL232503A (en) H2 - Indazoles as antagonists of the ep2 receptor
EP2685824A4 (en) INDOLE DERIVATIVES USEFUL AS CCR2ANTAGONISTS
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
PL2814825T3 (pl) Dihydrofuranowe pochodne azetydyny jako środki przeciwpasożytnicze